These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17043120)

  • 21. In vitro activities of linezolid, meropenem, and quinupristin-dalfopristin against group C and G streptococci, including vancomycin-tolerant isolates.
    Zaoutis T; Moore LS; Furness K; Klein JD
    Antimicrob Agents Chemother; 2001 Jul; 45(7):1952-4. PubMed ID: 11408207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.
    Ross JE; Anderegg TR; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 May; 52(1):53-8. PubMed ID: 15878443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
    Bogdanovich T; Esel D; Kelly LM; Bozdogan B; Credito K; Lin G; Smith K; Ednie LM; Hoellman DB; Appelbaum PC
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3325-33. PubMed ID: 16048943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
    Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides.
    Drago L; De Vecchi E; Nicola L; Colombo A; Gismondo MR
    J Antimicrob Chemother; 2004 Aug; 54(2):542-5. PubMed ID: 15215227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. UV-C-irradiation sublethal stress does not alter antibiotic susceptibility of the viridans group streptococci to β-lactam, macrolide, and fluoroquinolone antibiotic agents.
    Maeda Y; Coulter WA; Goldsmith CE; Cherie Millar B; Moore JE
    J Investig Clin Dent; 2012 Aug; 3(3):198-202. PubMed ID: 22887906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experimental study of the efficacy of linezolid alone and in combinations against experimental meningitis due to Staphylococcus aureus strains with decreased susceptibility to beta-lactams and glycopeptides.
    Cabellos C; Garrigós C; Taberner F; Force E; Pachón-Ibañez ME
    J Infect Chemother; 2014 Sep; 20(9):563-8. PubMed ID: 24973908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
    Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinetic bactericidal activity of telithromycin, azithromycin and clarithromycin against respiratory pathogens.
    Drago L; De Vecchi E; Nicola L; Legnani D; Gismondo MR
    APMIS; 2005 Oct; 113(10):655-63. PubMed ID: 16309423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries.
    Flamm RK; Farrell DJ; Mendes RE; Ross JE; Sader HS; Jones RN
    J Chemother; 2012 Dec; 24(6):328-37. PubMed ID: 23174097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activities of new fluoroquinolones, ketolides, and other antimicrobials against blood culture isolates of viridans group streptococci from across Canada, 2000.
    Gershon AS; de Azavedo JC; McGeer A; Ostrowska KI; Church D; Hoban DJ; Harding GK; Weiss K; Abbott L; Smaill F; Gourdeau M; Murray G; Low DE;
    Antimicrob Agents Chemother; 2002 May; 46(5):1553-6. PubMed ID: 11959597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.
    Jones RN; Ross JE; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2006 Feb; 57(2):279-87. PubMed ID: 16326811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients.
    Rolston K; Wang W; Nesher L; Coyle E; Shelburne S; Prince RA
    J Antibiot (Tokyo); 2014 Jul; 67(7):505-9. PubMed ID: 24824818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial activity of linezolid combined with minocycline against vancomycin-resistant Enterococci.
    Wu J; Jiang TT; Su JR; Li L
    Chin Med J (Engl); 2013 Jul; 126(14):2670-5. PubMed ID: 23876894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro antibacterial activity of beta-lactams and non-beta-lactams against Streptococcus pneumoniae isolates from Sydney, Australia.
    Gosbell IB; Fernandes LA; Fernandes CJ
    Pathology; 2006 Aug; 38(4):343-8. PubMed ID: 16916725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci.
    Livermore DM; Warner M; Mushtaq S; North S; Woodford N
    Antimicrob Agents Chemother; 2007 Mar; 51(3):1112-4. PubMed ID: 17210773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates.
    Tato M; de la Pedrosa EG; Cantón R; Gómez-García I; Fortún J; Martín-Davila P; Baquero F; Gomez-Mampaso E
    Int J Antimicrob Agents; 2006 Jul; 28(1):75-8. PubMed ID: 16774814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Linezolid surveillance program results for 2008 (LEADER Program for 2008).
    Farrell DJ; Mendes RE; Ross JE; Jones RN
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):392-403. PubMed ID: 19913682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries.
    Jones RN; Kohno S; Ono Y; Ross JE; Yanagihara K
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):191-201. PubMed ID: 19500528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
    Harnett SJ; Fraise AP; Andrews JM; Jevons G; Brenwald NP; Wise R
    J Antimicrob Chemother; 2004 May; 53(5):783-92. PubMed ID: 15056651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.